Ultra-Low-Dose Inhalation of Melphalan as an Additional Treatment for COVID-19-Associated Pneumonia

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(7), P. 2149 - 2149

Published: March 21, 2025

Background/Objectives: Effective anti-inflammatory treatment for COVID-19 is necessary. It was shown that ultra-low doses (100-fold lower than therapeutic ones) of alkylating drug melphalan (MEL) interact with cytokine cell receptors without DNA damage. A method treating severe MEL inhalations proposed. The objective to study the efficacy and safety pneumonia treatment. Methods: An open-label comparative (NCT04380376) 120 patients divided into two groups conducted. control group (CG) received standard treatment, (MG) also seven daily 0.1 mg inhalations. Changes in clinical improvement, inflammatory markers, CT lung scan data were primary secondary endpoints. Results: Patients MG showed significantly better outcomes compared CG, improvements dyspnea according WHO Ordinal Scale Clinical Improvement modified Borg Scale, scans, markers. No adverse effects (including irritant bronchoconstrictor effects) possibly related reported. Conclusions: This demonstrated incorporating ultra-low-dose regimen COVID-19-associated pneumonia. conclusion supported by a statistically significant improvement outcomes, as assessed OSCI, more rapid reduction severity dyspnea, marked effect, evidenced faster decline C-reactive protein levels. observed proposed method. Further large-scale randomized trials are warranted validate these findings evaluate potential implementation inhalation practice.

Language: Английский

Long COVID as a Disease of Accelerated Biological Aging: An Opportunity to Translate Geroscience Interventions

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 99, P. 102400 - 102400

Published: June 28, 2024

Language: Английский

One-year post-acute COVID-19 syndrome and mortality in South Korea: a nationwide matched cohort study using claims data

Frontiers in Public Health, Journal Year: 2024, Volume and Issue: 12

Published: July 10, 2024

Background Current understanding of post-COVID-19 syndrome in South Korea is primarily based on survey studies or research targeting specific patient groups, such as those hospitalized. Moreover, the majority relevant have been conducted European and North American populations, which may limit their applicability to Korean context. To address this gap, our study explores one-year outcomes COVID-19, focusing potential post-acute all-cause mortality Korea. Methods This retrospective cohort used nationwide claims data Korea, including adults aged >18 with records between January 20, 2020, February 25, 2021. Patients were classified into COVID-19 non-COVID-19 groups matched 1:1 propensity scores. Primary 12-month mortality. Results The involved 34,802 patients. group had significantly elevated risks coagulopathies (OR = 2.70 [2.24, 3.28]; p < 0.001), chronic lower respiratory diseases 1.96 [1.80, 2.14]; symptoms circulatory systems 1.91 2.04]; mood disorders 1.67 [1.51, 1.86]; cardiac 1.39 [1.21, 1.59]; cognition, perception, emotional state, behavior 1.15 [1.04, 1.27]; 0.005). All-cause was higher during 6 months 1.34 [1.06, 1.69]; 0.015), but gradually decreased, reaching an OR 0.996 ([0.83, 1.19]; 0.964) at 1 year. Conclusion In includes coagulopathies, issues, disorders, diseases. risk heightened for up months, then decreases resolves within a

Language: Английский